Back
#1
15.2%
Top 0.3%
15.2%
Top 0.9%
9.4%
Top 60%
9.4%
Top 0.3%
8.1%
Top 35%
6.7%
#1
6.7%
Top 0.4%
6.2%
Top 4%
4.0%
Top 4%
1.6%
Top 2%
1.2%
Top 6%
1.0%
Top 53%
1.0%
Top 5%
0.7%
Top 6%
0.7%
Top 23%
0.7%
Top 27%
0.5%
Baseline epigenetics as a biomarker of mepolizumab response in severe asthma
2025-09-04
respiratory medicine
Title + abstract only
View on medRxiv
Show abstract
Biologic treatment options have expanded considerably for severe asthma, transforming patient management, but only ~70% of patients respond to the treatment following standard criteria. This preliminary study utilized data collected in the Wessex AsThma CoHort of difficult asthma (WATCH) study. DNAm was measured in n=15 severe asthma patients at baseline, i.e., before mepolizumab (MEPO), an interleukin-5 receptor antagonist, was administered and the response to MEPO was analyzed. We aimed to as...
Predicted journal destinations
1
ERJ Open Research
36 training papers
2
European Respiratory Journal
44 training papers
3
BMJ Open Respiratory Research
32 training papers
4
PLOS ONE
1737 training papers
5
Thorax
29 training papers
6
Scientific Reports
701 training papers
7
Journal of Allergy and Clinical Immunology
15 training papers
8
American Journal of Respiratory and Critical Care Medicine
23 training papers
9
Frontiers in Immunology
140 training papers
10
iScience
74 training papers
11
Frontiers in Pharmacology
27 training papers
12
JCI Insight
63 training papers
13
Nature Communications
483 training papers
14
eClinicalMedicine
55 training papers
15
Medicine
29 training papers
16
Frontiers in Medicine
99 training papers
17
Journal of Clinical Medicine
77 training papers